GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline (GSK) is conducting a Phase 2 clinical trial titled ‘A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer.’ The study aims to evaluate the effectiveness of dostarlimab combined with carboplatin-paclitaxel, followed by dostarlimab monotherapy, in treating endometrial cancer. This research is significant as it explores potential new treatment options for a challenging cancer type.
The intervention involves the use of dostarlimab, a biological agent, alongside the chemotherapy drugs carboplatin and paclitaxel. Dostarlimab is administered intravenously, initially at 500 mg for six cycles, then increased to 1,000 mg from the seventh cycle. Carboplatin and paclitaxel are also administered intravenously during the first six cycles.
The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. This straightforward approach allows researchers to directly assess the treatment’s impact on participants.
The study began on May 7, 2024, with an active but not recruiting status as of the last update on July 24, 2025. These dates are crucial for tracking the study’s progress and anticipating future results.
This clinical trial update could influence GSK’s stock performance and investor sentiment, given the potential for new treatment options in the oncology market. Success in this trial could position GSK favorably against competitors in the pharmaceutical industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.